A European study recently demonstrated that switching Type 1 and Type 2 diabetes patients to a Tresiba prescription is cost-effective, according to manufacturer Novo Nordisk.
The analysis centered on a population drawn from the existing European Tresiba Audit (EU-TREAT) study tracking 2,550 individuals’ response to changing medications, measuring cost-effectiveness on several levels. Tresiba (insulin degludec) was compared to other basal insulins, including insulin glargine U100 and insulin detemir, according to an announcement.
Tresiba is administered as a once-daily dose to stabilize glucose levels. This study builds on previous evidence and shows that Tresiba allows for less variation in blood glucose numbers and a lower likelihood of hypoglycemia compared with insulin glargine U100, for example. Additionally, the medication affords a degree of flexibility should dosage times be altered.
"In addition to the body of evidence supporting its benefits in clinical practice, Tresiba has been shown to be a cost-effective treatment option across various European healthcare systems," Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk, said in the announcement. "We hope these encouraging findings from real-world clinical practice will help make Tresiba available to even more people living with type 1 and type 2 diabetes around the world."
Approved in 2012, Tresiba is commercially marketed in more than 50 countries and approved in over 80 nations.
